Next Article in Journal
UPLC-Q-TOF/MS Based Plasma Metabolomics for Identification of Paeonol’s Metabolic Target in Endometriosis
Previous Article in Journal
Visible-Light-Enhanced Antibacterial Activity of Silver and Copper Co-Doped Titania Formed on Titanium via Chemical and Thermal Treatments
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 2
10.3390/molecules28020651
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas)

by
Leyi Zhou
1,
Rufa L. Mendez
1 and
Jung Yeon Kwon
1,2,*
1
Department of Food Science and Technology, College of Agricultural Sciences, Oregon State University, Corvallis, OR 97333, USA
2
Seafood Research and Education Center, Oregon State University, Astoria, OR 97103, USA
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(2), 651; https://doi.org/10.3390/molecules28020651
Submission received: 6 November 2022 / Revised: 28 December 2022 / Accepted: 3 January 2023 / Published: 9 January 2023
Browse Figure
Versions Notes

Abstract

:
Pacific oyster (Crassostrea gigas), an abundant bivalve consumed across the Pacific, is known to possess a wide range of bioactivities. While there has been some work on its bioactive hydrolysates, the discovery of bioactive peptides (BAPs) remains limited due to the resource-intensive nature of the existing discovery pipeline. To overcome this constraint, in silico-based prospecting is employed to accelerate BAP discovery. Major oyster proteins were digested virtually under a simulated gastrointestinal condition to generate virtual peptide products that were screened against existing databases for peptide bioactivities, toxicity, bitterness, stability in the intestine and in the blood, and novelty. Five peptide candidates were shortlisted showing antidiabetic, anti-inflammatory, antihypertensive, antimicrobial, and anticancer potential. By employing this approach, oyster BAPs were identified at a faster rate, with a wider applicability reach. With the growing market for peptide-based nutraceuticals, this provides an efficient workflow for candidate scouting and end-use investigation for targeted functional product preparation.

1. Introduction

Bioactive peptides (BAPs) are short peptides, usually 2–20 residues in length [1], that can exhibit a positive impact on human health through mitigating various molecular pathways implicated in chronic disease development. Dietary proteins are a widely available and accessible source of bioactive peptides. The human digestive system can, among many other methods such as food processing, fermentation, enzymatic and chemical hydrolysis [2], effectively release cryptic BAPs within food proteins through the hydrolytic action by digestive proteases. Therefore, the bioactive potential of plant and animal proteins liberated during digestion has been widely studied through in vitro, in vivo, and in silico approaches [3,4]. Many functional food products and ingredients that carry food-derived bioactive peptides are commercially available [5].
Marine organisms have gained tremendous research interest in their bioactivity and therapeutic potential [6,7]. Oysters are the most cultured shellfish worldwide [8] and are traditionally used as medicine for various purposes in Asia [9]. They are nutrient-dense, high in protein, low in fat, and rich in various micronutrients and bioactive components. Pacific oyster (Crassostrea gigas) has shown promise experimentally exhibiting various bioactivities including antimicrobial, antioxidant, anti-inflammatory, angiotensin-converting enzyme (ACE)-inhibitory, anti-cancer, and promotion of sexual reproductive hormones [8,10,11]. Therefore, C. gigas demonstrates immense opportunity as a BAP precursor in a wide range of bioactivity classes for functional food and nutraceutical application. BAPs bring key advantages including high target specificity, potency, and low toxicity compared to small molecule drugs. However, the main challenges in translating BAP research remain their questionable bioavailability, stability in digestion and circulation, and bitterness [12,13]. To circumvent these disadvantages in new BAP discovery, in silico screening and prediction methods may be applied. Many studies examining bioactive peptides have effectively incorporated in silico methods to accelerate the conventional BAP discovery process, thereby achieving higher precision, time, cost, and resource savings [14,15,16,17]. While there are many studies mining the bioactive potential and BAP sequences from C. gigas and related species, few have integrated in silico methods to cover a wider candidate pool than the physical samples and available reagents may allow [15,18]. In this present study, we set out to identify novel BAP candidates from C. gigas flesh released by human consumption using in-silico screening methods and develop a transferrable pipeline for the in silico discovery of BAPs from GI-digested food proteins.

2. Results

2.1. Simulated Gastrointestinal Digestion

The enzymatic hydrolysis on all 13 selected C. gigas proteins with human digestive enzymes, pepsin, trypsin, and chymotrypsin (Table 1) resulted in 1800 total protein fragments (excluding single amino acids) via BIOPEP Enzyme Action Tool and ExPASy PeptideCutter combined. The peptide lengths ranged from 2 to 16 residues. The resulting peptide profiles from each protein are shown in Figure 1. To maximize the potential for novelty and specificity to oyster origin while maintaining bioavailability, only peptides of 5 to 10 residues in length were selected for further analyses, which narrowed down the candidate pool to a total of 289 unique peptide sequences. ToxinPred and iBitter-SCM revealed 126 bitter peptides, one of which is also predicted to be toxic. Only the remaining 163 unique non-toxic, non-bitter peptides were considered for further analysis. HLP analysis shows that all but two remaining peptide candidates have high intestinal stability, defined by half-life > 1.0 s, while PLifePred analysis predicted plasma half-life ranging from 757.01 to 1058.51 s. Most natural food-derived peptides have a half-life between 800 to 900 s based on PLifePred from Gülseren and Vahapoglu’s [19] investigation of 3074 peptides from 12 different food sources. Therefore, a threshold half-life of 800 s or above was chosen to benchmark for relatively high C. gigas peptide stability in the blood. From the multiple database scans, only one sequence AGDDAPR from the peptide list was previously reported as a bioactive peptide record in BIOPEP and EROP-Moscow databases, with ACE-inhibiting, antioxidative, Pancreatic lipase-inhibiting, and alpha-amylase-inhibiting activities. With our comprehensive screening phase detailed above, 151 nontoxic, non-bitter, highly stable, and novel sequences remained for bioactivity screening in silico, shown in Table 2.

2.2. Prospect Oyster BAPs

From the BAP candidate pool (151 sequences), 22 were shortlisted based on their predicted bioactivities in various in silico platforms performed (Table 3). Sequences were considered high potential/prospect BAPs when they gain scores beyond the established predictive model threshold and when these consistently show interaction on some known binding sites associated with each target bioactivity. Oyster antihypertensive peptides (AHPs) were selected based on AHTpin scores (>1.0) and predicted binding to all three active site residues of human angiotensin-converting enzyme (ACE1) with PepSite2; a full analysis is shown in Table 4. Candidate AHPs were further shortlisted based on predicted bioavailability indices, namely <30% predicted human intestinal absorption and <20% bioavailability score using ADMETlab2.0 (Supplementary Table S2).
Antidiabetic peptides (ADPs) were selected based on iDPPIV-SCM scores (> 350) with at least two binding sites for human dipeptidyl peptidase (DPPIV) when analyzed using PepSite2 (Table 5). High-confidence anti-inflammatory peptides (AIPs) were predicted by both PreAIP and Antiinflam were ranked to select the top four peptides. The top antimicrobial peptide (AMP) selection cutoffs were set at CAMP-SVM = 1, CAMP-RF > 0.54, ADAM > 2. The only positive hit in DBAASP v3′s General Antimicrobial Activity prediction result was also included. The three most recent and performance-optimized anti-cancer peptide prediction servers, ACPred, iDACP, and mACPpred were chosen from a wide range of available tools. Positive cross-hits from all three platforms were selected as the top three anti-cancer peptides.

3. Discussion

The ease and efficiency of in silico approach have fueled its increasing traction in the predictive screening of BAPs, especially combining with or preceding the traditional in vitro/in vivo experiments. Meanwhile, a growing and diversifying pool of in silico tools is being developed and improved. This presents a huge opportunity to define an adaptable workflow for effective BAP scouting using the latest tools. Pacific oyster has shown tremendous potential with their wide range of associated bioactivities [8]. Therefore, using C. gigas as a case study, we have outlined an applicable framework using existing publicly accessible in silico tools to efficiently scope for novel BAPs from commonly consumed seafood.
In silico proteolysis is an efficient way to simulate GI digestion, since the oyster proteins are often consumed directly. Both available platforms, BIOPEP Enzyme Action Tool and ExPASy PeptideCutter, present two sets of pepsin and chymotrypsin subtypes: pepsin at pH = 1.3 vs pH > 2; chymotrypsin A with low or high specificity. However, recent studies which adopted in silico simulated GI digestion used discordant enzyme choices without a clear explanation of the selections [3,25,26,27,28]. Such a variation presents a potential understanding gap in applying the platforms. In comparison, the human pepsin A3 information as documented in the peptidase database MEROPS (A01.001) better matches the cleavage preferences and lower specificity of pepsin at pH > 2 (Table 2). In addition, the lower specificity yields shorter and more digestion-tolerant peptide products, which is preferable for an overhaul of bio-accessible fragments. Similarly, human digestive chymotrypsin A’s catalytic activity from its MEROPS (S01.152) entry is a much better match to low specificity chymotrypsin A’s activity in the hydrolysis platforms and can produce highly digestive-tolerant peptides. Finally, the comparisons led to the best-aligned enzyme choices used for this study, indicated in Table 2.
The peptide distribution post-digestion in Figure 1 shows muscle proteins, particularly myosin and paramyosin, yielded greater proportions of short peptides, which indicates higher digestibility with dietary relevance as muscle proteins are highly abundant in the flesh [15]. One caveat is that both digestion tools assume no protein folding which could restrict enzyme access. Under real-life gut conditions, there might be fewer cleavages made than virtually generated.
The outputs from both digestion tools, BIOPEP Enzyme Action Tool and ExPASy PeptideCutter were included collectively due to the observation that only a small portion of peptide results overlapped, with only di- and tripeptides, despite using the same set of enzymes. We suspected that the enzyme’s cleavage sites were encoded differently. As evident in Figure 1, BIOPEP generated predominantly di- and tripeptides, and very few oligopeptides. In fact, the sequence length range of five to ten residues has no overlapping results between the two platforms. Table 2 details the enzyme cleavage information cited in the respective server page, which shows slight variation between the two platforms both based on the references and the resulting sequences. Therefore, pooling all resulting peptides from both sources helps maximize the chance to identify potential bioactive peptides.
A peptide length range of 5 to 10 residues was determined to balance and maximize bioavailability and novelty. Bioactive peptides can transport from the gut lumen through the intestinal epithelium into the bloodstream, by four possible pathways: PepT1-mediated permeation, paracellular transport through tight junctions, transcytosis via vesicles, and passive transcellular diffusion [29]. Xu et al.’s review [29] also presented BAPs in this length range that can cross the Caco-2 cell monolayers via the above mechanisms, with high permeability coefficients comparable to shorter peptides. Another reason to exclude di-, tri-and tetra-peptides from our study is the ubiquity of short peptides which makes them more likely to be omnipresent in various food sources. For example, dipeptide VY possesses antihypertensive activity but is shared by sardines, seaweed, sesame, and royal jelly products among commercialized bioactive peptide products [2]. Therefore, our peptide size filter will help maximize novelty by uncovering new and uniquely oyster sequences.
From enzymatic digestion to preliminary screening against unwanted attributes, to final in silico bioactivity scoping, the peptide candidate pool has been narrowed down from 1800 total peptide products post-digestion, with 308 sequences in the 5 to 10 residue length range, to 151 unique non-toxic, non-bitter, stable, and novel peptide candidates, then finally to 22 top sequences with high potential bioactivities. Such a sequential funnel procedure can greatly improve the breadth and power of BAP screening. The selected activity prediction servers in this study utilize a variety of Machine Learning algorithm-based models. Top BAP candidates in the final shortlist have scored highly across multiple predictors, whose model construction and datasets have been vetted for reliability. In addition, PepSite2 analysis complements the predictions by modeling the extent of protein-peptide interaction for enzyme inhibitory mechanisms.
Amino acid and dipeptide compositions combined with physicochemical properties are also helpful to elucidate shared features and trends in new and known BAPs. The peptides with strong ACE-inhibitory activity likely contain C-terminal proline, hydrophobic, aliphatic, branched, aromatic, or positively charged residues, N-terminal branched chain, or hydrophobic residues [30,31,32,33]. In addition, proline-containing peptides generally help resist digestion [1,2]. The peptides with strong DPPIV-inhibitory activity likely contain F, R, and Y residues [34]. C-terminal proline and DPP-IV substrate motif at the N-terminal, Xaa-Pro, or Xaa-A may act as DPP-IV inhibitors [35,36]. Anti-inflammatory peptides benefit from hydrophobic residues at the termini, and high hydrophobic residue content has shown stronger NO inhibition ability in vitro [37,38]. They have also shown an association with positively charged residues, though inconsistent findings have been reported [39,40]. Antimicrobial peptides (AMPs) are generally amphiphilic with hydrophobic and cationic residues, mainly lysine and arginine, to facilitate interaction with the negatively charged microbial lipid cell membranes [41,42,43,44]. A subset of AMPs can also serve as anticancer peptides with selective membranolytic and cytolytic activities. These anticancer peptides generally contain 5–30 residues in length, and as with AMPs, hydrophobic and cationic (preferably by lysine) and amphiphilic properties are significant to their diverse modes of action [42,45,46], while cysteine-rich domains can form stabilized scaffolds to help maintain extracellular motifs and structures [46,47]. Our shortlisted peptides in Table 3 show general consistency with previously reported composition and property trends detailed above. Nevertheless, no conclusive causal relationship has been drawn between sequence-based propensities and bioactivities. Additional research investigating how the sequence, structure, and properties of BAPs enable their mechanistic action is warranted.
On the other hand, there remains an opportunity to strengthen the proposed framework by incorporating more in-depth 3-D structural analyses. The current study is limited to PepSite2 comparative assessment of the best docking model of protein-peptide interactions, which is applicable to only two out of five bioactivities assessed. Yuan et al.’s recent work on ACE- and DPP-IV-inhibitory peptides from C. gigas followed a similar investigation process but included a docking study analyzed based on CDOCKER interaction energy, a CHARMm-based molecular docking algorithm [48]. The CDOCKER scores indicate ligand binding affinities calculated at different poses of simulated receptor-ligand binding modes. The accuracy and reliability of such molecular docking methods in reproducing experimental observations have shown promise to elucidate molecular mechanisms of small ligands. Although we have narrowed down and identified different BAPs from the same source and digestion process, the in silico platform selection and parameter settings greatly influence the filtering results. For example, in contrast to Yuan et al.’s study, we opted not to use PeptideRanker, (http://bioware.ucd.ie/~compass/biowareweb/Serverpages/peptideranker.php/, accessed on 10 January 2022), a widely utilized general bioactivity predictor built on an N-1 Neural Network (N1-NN) model based on shared features across various functional classes of BAPs [49]. However, its three classes of BAPs only included antimicrobial peptides, peptide hormones, and peptide toxins/venom. The training dataset is made up of heavily AMPs, including sources from BIOPEP, PeptideDB, APD2, and CAMP. Therefore, within the five bioactivities of interest in this study, we expected PeptideRanker scoring to be skewed towards AMPs.
Future work following up this study may adopt and cross-check using optimized molecular docking software such as flexible CDOCKER and AutoDock [50,51,52], as well as quantitative structure-activity relationship (QSAR) analysis to complement the proposed screening strategy. For example, membrane permeability can be modeled for predicted AMPs with Gram-positive or Gram-negative bacteria, associated with probable antibacterial activity. Going forward, this framework shall be continually updated and optimized with the frequent release of new tools and findings. It may also branch out to include other production methods of BAPs such as via commercial enzymes and microbial fermentation. We also suggest future in vitro validation in two ways. From a top-down approach, enzyme digestion can be performed to mirror the in silico process in this study. Peptidomic analysis can be performed to compare the peptide product profile to that from BIOPEP Enzyme Action Tool and PeptideCutter results. Additionally, bioactivity assays can be performed on both hydrolysates and synthetic peptides of the top candidate sequences from this study to confirm predicted bioactivity and potency.

4. Materials and Methods

4.1. Protein Selection and Retrieval

C. gigas protein sequences and information were retrieved from the UniProt Knowledgebase (https://www.uniprot.org/uniprotkb/, accessed on 15 November, 2021). Only SwissProt-reviewed entries, and major proteins identified through proteomics from recent literature were included. From the SwissProt database, all nine manually annotated and reviewed protein sequences of C. gigas expressed in the oyster flesh were included. In addition to the database search, we also included the 5 prominent C. gigas proteins identified through SDS-PAGE and subsequent nanoLC-nanoESI-MS/MS analysis [15] to strengthen the abundant protein inclusion criteria. The information on all 13 proteins analyzed in this study is listed in Table 6.

4.2. Enzyme Hydrolysis Using BIOPEP and ExPASy PeptideCutter

Simulated human gastrointestinal (GI) digestion was performed with enzymes pepsin pH > 2 (EC 3.4.23.1), trypsin (EC 3.4.21.4), and chymotrypsin A (EC 3.4.21.1) in both programs, BIOPEP-UVM’s Enzyme Action Tool (https://biochemia.uwm.edu.pl/en/biopep-uwm-2/, accessed on 21 December 2021) and ExPASy PeptideCutter (https://web.expasy.org/peptide_cutter/, accessed on 21 December 2021). The unique peptide sequence outputs were collated. Peptides in the length range of 5 to 10 residues were included for further analysis.

4.3. Toxicity, Bitterness, Stability, and Allergenicity Screening

All virtually generated peptide products were subjected to multiple database searches as peptide queries in FASTA form. ToxinPred (https://webs.iiitd.edu.in/raghava/toxinpred/multiple_test.php/, accessed on 10 January 2022), a support vector machine (SVM)-based prediction method with a threshold score of 0.0, was chosen to screen for non-specific peptide cytotoxicity. Digestion peptide products predicted as toxic were excluded. iBitter-SCM (http://camt.pythonanywhere.com/iBitter-SCM/, accessed on 10 January 2022) was used as the bitterness screening tool. Any peptides scoring above the threshold of 333 were predicted to be bitter-tasting, and therefore excluded from subsequent analyses. PLifePred (https://webs.iiitd.edu.in/raghava/plifepred/, accessed on 1 February 2022) was used to assess peptide stability in blood. Peptides with predicted half-life values above 800 s are included. HLP (https://webs.iiitd.edu.in/raghava/hlp/, http://crdd.osdd.net/raghava/hlp/interactive.htm/, accessed on 1 February 2022) was used to assess peptide stability in the intestinal environment. Additionally, our peptide pool was checked against reported allergenic motifs of the major oyster allergen tropomyosin Cra g1 [53,54,55], along with BIOPEP-UVM’s Allergenic Proteins and their Epitopes database, listed in Supplementary Table S1. No matches were found to be excluded from subsequent analysis.

4.4. Bioactivity and Novelty Assessments

All non-toxic, non-bitter, stable, and nonallergenic oyster peptides were screened against bioactivity platforms and peptide repositories to favor the discovery of novel antihypertensive, antidiabetic, anti-inflammatory, antimicrobial, and anticancer peptides. Positive peptide hits for bioactivity that have not been recorded in the existing databases are extracted as the potential bioactive peptide longlist. The servers used are collated in Table 7.
These BAP candidates were then screened against BIOPEP-UVM, PepBank (http://pepbank.mgh.harvard.edu/, accessed on 10 March 2022), PeptideDB (http://www.peptides.be/, accessed on 10 March 2022), EROP-Moscow (http://erop.inbi.ras.ru/index.html/, accessed on 10 March 2022), and BioPepDB (http://bis.zju.edu.cn/biopepdbr/index.php/, accessed on 11 April 2022) to ensure that they are not yet recorded and reported.
In addition, PepSite2 (http://pepsite2.russelllab.org/, accessed on 5 May 2022) was adopted to predict the binding site interactions between BAP candidates and human ACE (PDB entry 1O86) or dipeptidyl peptidase-4 enzyme (DPP-IV) (PDB entry 2ONC) respectively, using Mohd Salim and Gan’s analysis procedure with minor modifications [17]. The top-ranked sequences and cross-hits between platforms for each bioactivity were finally selected as high-potential bioactive peptides, shortlisted in Table 3.

5. Conclusions

The present study presents an in silico-based approach to discover novel bioactive peptides from C. gigas by investigating a wide range of protein and peptide-level databases and tools. A promising bioactive peptide candidate shortlist is provided for antihypertensive, antidiabetic, anti-inflammatory, and anti-cancer activities. These novel BAPs are predicted to be non-toxic, non-bitter, bioavailable, and stable in the intestines and circulation. Based on their predictive bioactivities, it will be of value to validate these bioactivities and explore potency in terms of hydrolysate preparation.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28020651/s1, Table S1: Allergenic motifs previously reported in Crassostrea gigas Tropomyosin Cra g 1. Table S2: Absorption parameters and physico-chemical properties of positively scored bioactive peptide candidates retrieved from ADMETlab2.0 and ProtParam.

Author Contributions

Conceptualization, L.Z., R.L.M. and J.Y.K.; methodology, L.Z. and R.L.M.; investigation, L.Z.; formal analysis, L.Z.; writing—original draft preparation; L.Z.; supervision, J.Y.K.; writing—reviewing and editing, J.Y.K. and R.L.M.; funding acquisition, J.Y.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported in part by the funding from Oregon Agricultural Experiment Station.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are not available from the authors.

Abbreviations

BAPbioactive peptide
C. gigasCrassostrea gigas
T2Dtype 2 diabetes
DPP-IVdipeptidyl peptidase-4
ACEangiotensin-converting enzyme
SVMsupport vector machine
RFRandom Forest
ADMETabsorption, distribution, metabolism and excretion properties, and toxicities
QSARquantitative structure-activity relationship
GIgastrointestinal

References

  1. Chalamaiah, M.; Keskin Ulug, S.; Hong, H.; Wu, J. Regulatory Requirements of Bioactive Peptides (Protein Hydrolysates) from Food Proteins. J. Funct. Foods 2019, 58, 123–129. [Google Scholar] [CrossRef]
  2. Hayes, M.; Tiwari, B.K. Bioactive Carbohydrates and Peptides in Foods: An Overview of Sources, Downstream Processing Steps and Associated Bioactivities. Int. J. Mol. Sci. 2015, 16, 22485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Barati, M.; Javanmardi, F.; Mousavi Jazayeri, S.M.H.; Jabbari, M.; Rahmani, J.; Barati, F.; Nickho, H.; Davoodi, S.H.; Roshanravan, N.; Mousavi Khaneghah, A. Techniques, Perspectives, and Challenges of Bioactive Peptide Generation: A Comprehensive Systematic Review. Compr. Rev. Food Sci. Food Saf. 2020, 19, 1488–1520. [Google Scholar] [CrossRef] [PubMed]
  4. Udenigwe, C.C.; Aluko, R.E. Food Protein-Derived Bioactive Peptides: Production, Processing, and Potential Health Benefits. J. Food Sci. 2012, 77, R11–R24. [Google Scholar] [CrossRef] [PubMed]
  5. Hartmann, R.; Meisel, H. Food-Derived Peptides with Biological Activity: From Research to Food Applications. Curr. Opin. Biotechnol. 2007, 18, 163–169. [Google Scholar] [CrossRef]
  6. Kim, S.-K.; Wijesekara, I. Development and Biological Activities of Marine-Derived Bioactive Peptides: A Review. J. Funct. Foods 2010, 2, 1–9. [Google Scholar] [CrossRef]
  7. Ngo, D.-H.; Vo, T.-S.; Ngo, D.-N.; Wijesekara, I.; Kim, S.-K. Biological Activities and Potential Health Benefits of Bioactive Peptides Derived from Marine Organisms. Int. J. Biol. Macromol. 2012, 51, 378–383. [Google Scholar] [CrossRef]
  8. Hao, L.; Wang, X.; Cao, Y.; Xu, J.; Xue, C. A Comprehensive Review of Oyster Peptides: Preparation, Characterisation and Bioactivities. Rev. Aquac. 2022, 14, 120–138. [Google Scholar] [CrossRef]
  9. Zhang, L.; Liu, Y.; Tian, X.; Tian, Z. Antimicrobial Capacity and Antioxidant Activity of Enzymatic Hydrolysates of Protein from Rushan Bay Oyster (Crassostrea Gigas). J. Food Process. Preserv. 2015, 39, 404–412. [Google Scholar] [CrossRef]
  10. Lee, H.-J.; Saravana, P.S.; Cho, Y.-N.; Haq, M.; Chun, B.-S. Extraction of Bioactive Compounds from Oyster (Crassostrea gigas) by Pressurized Hot Water Extraction. J. Supercrit. Fluids 2018, 141, 120–127. [Google Scholar] [CrossRef]
  11. Zhang, W.; Wei, Y.; Cao, X.; Guo, K.; Wang, Q.; Xiao, X.; Zhai, X.; Wang, D.; Huang, Z. Enzymatic Preparation of Crassostrea Oyster Peptides and Their Promoting Effect on Male Hormone Production. J. Ethnopharmacol. 2021, 264, 113382. [Google Scholar] [CrossRef] [PubMed]
  12. Apostolopoulos, V.; Bojarska, J.; Chai, T.-T.; Elnagdy, S.; Kaczmarek, K.; Matsoukas, J.; New, R.; Parang, K.; Lopez, O.P.; Parhiz, H.; et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules 2021, 26, 430. [Google Scholar] [CrossRef] [PubMed]
  13. Udenigwe, C.C. Bioinformatics Approaches, Prospects and Challenges of Food Bioactive Peptide Research. Trends Food Sci. Technol. 2014, 36, 137–143. [Google Scholar] [CrossRef]
  14. Chen, J.; Yu, X.; Chen, Q.; Wu, Q.; He, Q. Screening and Mechanisms of Novel Angiotensin-I-Converting Enzyme Inhibitory Peptides from Rabbit Meat Proteins: A Combined in Silico and in Vitro Study. Food Chem. 2022, 370, 131070. [Google Scholar] [CrossRef]
  15. Gomez, H.L.R.; Peralta, J.P.; Tejano, L.A.; Chang, Y.-W. In Silico and In Vitro Assessment of Portuguese Oyster (Crassostrea angulata) Proteins as Precursor of Bioactive Peptides. Int. J. Mol. Sci. 2019, 20, 5191. [Google Scholar] [CrossRef] [Green Version]
  16. Manzoor, M.; Singh, J.; Gani, A. Exploration of Bioactive Peptides from Various Origin as Promising Nutraceutical Treasures: In Vitro, in Silico and in Vivo Studies. Food Chem. 2022, 373, 131395. [Google Scholar] [CrossRef]
  17. Mohd Salim, M.A.S.; Gan, C.-Y. Dual-Function Peptides Derived from Egg White Ovalbumin: Bioinformatics Identification with Validation Using in Vitro Assay. J. Funct. Foods 2020, 64, 103618. [Google Scholar] [CrossRef]
  18. Feng, C.; Tian, L.; Jiao, Y.; Tan, Y.; Liu, C.; Luo, Y.; Hong, H. The Effect of Steam Cooking on the Proteolysis of Pacific Oyster (Crassostrea gigas) Proteins: Digestibility, Allergenicity, and Bioactivity. Food Chem. 2022, 379, 132160. [Google Scholar] [CrossRef]
  19. Gülseren, İ.; Vahapoglu, B. The Stability of Food Bioactive Peptides in Blood: An Overview. Int. J. Pept. Res. Ther. 2021, 28, 2. [Google Scholar] [CrossRef]
  20. Keil, B. Specificity of Proteolysis; Springer: Berlin/Heidelberg, Germany, 1992; ISBN 978-3-642-48382-0. [Google Scholar]
  21. Arai, S.; Fukimaji, M. Enzymatic Modification of Proteins with Special Reference to Improving Their Functional Properties. In Food Enzymology; Elsevier Applied Science: London, UK, 1991; Volume 2, pp. 83–104. [Google Scholar]
  22. Zhang, C.; Wu, S.; Xu, D. Catalytic Mechanism of Angiotensin-Converting Enzyme and Effects of the Chloride Ion. J. Phys. Chem. B 2013, 117, 6635–6645. [Google Scholar] [CrossRef]
  23. Wang, X.; Wu, S.; Xu, D.; Xie, D.; Guo, H. Inhibitor and Substrate Binding by Angiotensin-Converting Enzyme: Quantum Mechanical/Molecular Mechanical Molecular Dynamics Studies. J. Chem. Inf. Model. 2011, 51, 1074–1082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV. Structure 2003, 11, 947–959. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kose, A. In Silico Bioactive Peptide Prediction from The Enzymatic Hydrolysates of Edible Seaweed Rubisco Large Chain. Turk. J. Fish. Aquat. Sci. 2021, 21, 615–625. [Google Scholar] [CrossRef]
  26. Pripp, A.H. Initial Proteolysis of Milk Proteins and Its Effect on Formation of ACE-Inhibitory Peptides during Gastrointestinal Proteolysis: A Bioinformatic, In Silico, Approach. Eur. Food Res. Technol. 2005, 221, 712–716. [Google Scholar] [CrossRef]
  27. Wang, Y.; Li, S.; Guan, C.; He, D.; Liao, X.; Wang, Y.; Chen, H.; Zhang, C.; Xing, X.-H. Functional discovery and production technology for natural bioactive peptides. Sheng Wu Gong Cheng Xue Bao Chin. J. Biotechnol. 2021, 37, 2166–2180. [Google Scholar] [CrossRef]
  28. Lafarga, T.; O’Connor, P.; Hayes, M. Identification of Novel Dipeptidyl Peptidase-IV and Angiotensin-I-Converting Enzyme Inhibitory Peptides from Meat Proteins Using in Silico Analysis. Peptides 2014, 59, 53–62. [Google Scholar] [CrossRef] [PubMed]
  29. Xu, Q.; Hong, H.; Wu, J.; Yan, X. Bioavailability of Bioactive Peptides Derived from Food Proteins across the Intestinal Epithelial Membrane: A Review. Trends Food Sci. Technol. 2019, 86, 399–411. [Google Scholar] [CrossRef]
  30. Aluko, R.E. Structure and Function of Plant Protein-Derived Antihypertensive Peptides. Curr. Opin. Food Sci. 2015, 4, 44–50. [Google Scholar] [CrossRef]
  31. Jakubczyk, A.; Karaś, M.; Rybczyńska-Tkaczyk, K.; Zielińska, E.; Zieliński, D. Current Trends of Bioactive Peptides—New Sources and Therapeutic Effect. Foods 2020, 9, 846. [Google Scholar] [CrossRef]
  32. Sitanggang, A.B.; Putri, J.E.; Palupi, N.S.; Hatzakis, E.; Syamsir, E.; Budijanto, S. Enzymatic Preparation of Bioactive Peptides Exhibiting ACE Inhibitory Activity from Soybean and Velvet Bean: A Systematic Review. Molecules 2021, 26, 3822. [Google Scholar] [CrossRef]
  33. Vermeirssen, V.; Camp, J.V.; Verstraete, W. Bioavailability of Angiotensin I Converting Enzyme Inhibitory Peptides. Br. J. Nutr. 2004, 92, 357–366. [Google Scholar] [CrossRef] [PubMed]
  34. Harnedy, P.A.; Parthsarathy, V.; McLaughlin, C.M.; O’Keeffe, M.B.; Allsopp, P.J.; McSorley, E.M.; O’Harte, F.P.M.; FitzGerald, R.J. Atlantic Salmon (Salmo Salar) Co-Product-Derived Protein Hydrolysates: A Source of Antidiabetic Peptides. Food Res. Int. 2018, 106, 598–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Hatanaka, T.; Inoue, Y.; Arima, J.; Kumagai, Y.; Usuki, H.; Kawakami, K.; Kimura, M.; Mukaihara, T. Production of Dipeptidyl Peptidase IV Inhibitory Peptides from Defatted Rice Bran. Food Chem. 2012, 134, 797–802. [Google Scholar] [CrossRef] [PubMed]
  36. Nongonierma, A.B.; FitzGerald, R.J. Inhibition of Dipeptidyl Peptidase IV (DPP-IV) by Proline Containing Casein-Derived Peptides. J. Funct. Foods 2013, 5, 1909–1917. [Google Scholar] [CrossRef] [Green Version]
  37. He, R.; Wang, Y.; Yang, Y.; Wang, Z.; Ju, X.; Yuan, J. Rapeseed Protein-Derived ACE Inhibitory Peptides LY, RALP and GHS Show Antioxidant and Anti-Inflammatory Effects on Spontaneously Hypertensive Rats. J. Funct. Foods 2019, 55, 211–219. [Google Scholar] [CrossRef]
  38. Yuan, L.; Chu, Q.; Wu, X.; Yang, B.; Zhang, W.; Jin, W.; Gao, R. Anti-Inflammatory and Antioxidant Activity of Peptides from Ethanol-Soluble Hydrolysates of Sturgeon (Acipenser schrenckii) Cartilage. Front. Nutr. 2021, 8, 689648. [Google Scholar] [CrossRef]
  39. Guha, S.; Majumder, K. Structural-Features of Food-Derived Bioactive Peptides with Anti-Inflammatory Activity: A Brief Review. J. Food Biochem. 2019, 43, e12531. [Google Scholar] [CrossRef] [Green Version]
  40. Zhao, L.; Wang, X.; Zhang, X.-L.; Xie, Q.-F. Purification and Identification of Anti-Inflammatory Peptides Derived from Simulated Gastrointestinal Digests of Velvet Antler Protein (Cervus elaphus Linnaeus). J. Food Drug Anal. 2016, 24, 376–384. [Google Scholar] [CrossRef] [Green Version]
  41. Chung, C.-R.; Jhong, J.-H.; Wang, Z.; Chen, S.; Wan, Y.; Horng, J.-T.; Lee, T.-Y. Characterization and Identification of Natural Antimicrobial Peptides on Different Organisms. Int. J. Mol. Sci. 2020, 21, 986. [Google Scholar] [CrossRef] [Green Version]
  42. Gaspar, D.; Veiga, A.S.; Castanho, M.A.R.B. From Antimicrobial to Anticancer Peptides. A Review. Front. Microbiol. 2013, 4, 294. [Google Scholar] [CrossRef]
  43. Seo, M.-D.; Won, H.-S.; Kim, J.-H.; Mishig-Ochir, T.; Lee, B.-J. Antimicrobial Peptides for Therapeutic Applications: A Review. Molecules 2012, 17, 12276–12286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Wang, X.; Mishra, B.; Lushnikova, T.; Narayana, J.L.; Wang, G. Amino Acid Composition Determines Peptide Activity Spectrum and Hot-Spot-Based Design of Merecidin. Adv. Biosyst. 2018, 2, 1700259. [Google Scholar] [CrossRef] [PubMed]
  45. Charoenkwan, P.; Chiangjong, W.; Lee, V.S.; Nantasenamat, C.; Hasan, M.M.; Shoombuatong, W. Improved Prediction and Characterization of Anticancer Activities of Peptides Using a Novel Flexible Scoring Card Method. Sci. Rep. 2021, 11, 3017. [Google Scholar] [CrossRef]
  46. Chiangjong, W.; Chutipongtanate, S.; Hongeng, S. Anticancer Peptide: Physicochemical Property, Functional Aspect and Trend in Clinical Application (Review). Int. J. Oncol. 2020, 57, 678–696. [Google Scholar] [CrossRef] [PubMed]
  47. Prabhu, S.; Dennison, S.R.; Lea, B.; Snape, T.J.; Nicholl, I.D.; Radecka, I.; Harris, F. Anionic Antimicrobial and Anticancer Peptides from Plants. Crit. Rev. Plant Sci. 2013, 32, 303–320. [Google Scholar] [CrossRef]
  48. Yuan, Z.; Li, C.; Shuo, J.; Yishan, L.; Yannan, C.; Wenjie, L.; Bin, Z. Bioinformatics Identification and Molecular Mechanism of Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-IV Inhibitory Peptides from in Silico Digest of Crassostrea Gigas. Food Meas. 2022, 16, 4540–4550. [Google Scholar] [CrossRef]
  49. Mooney, C.; Haslam, N.J.; Pollastri, G.; Shields, D.C. Towards the Improved Discovery and Design of Functional Peptides: Common Features of Diverse Classes Permit Generalized Prediction of Bioactivity. PLoS ONE 2012, 7, e45012. [Google Scholar] [CrossRef] [Green Version]
  50. Gagnon, J.K.; Law, S.M.; Brooks III, C.L. Flexible CDOCKER: Development and Application of a Pseudo-Explicit Structure-Based Docking Method within CHARMM. J. Comput. Chem. 2016, 37, 753–762. [Google Scholar] [CrossRef] [Green Version]
  51. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [Green Version]
  52. Trott, O.; Olson, A.J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef]
  53. Fang, L.; Li, G.; Zhang, J.; Gu, R.; Cai, M.; Lu, J. Identification and Mutational Analysis of Continuous, Immunodominant Epitopes of the Major Oyster Allergen Crag 1. Clin. Immunol. 2019, 201, 20–29. [Google Scholar] [CrossRef] [PubMed]
  54. Marti, P.; Truffer, R.; Stadler, M.B.; Keller-Gautschi, E.; Crameri, R.; Mari, A.; Schmid-Grendelmeier, P.; Miescher, S.M.; Stadler, B.M.; Vogel, M. Allergen Motifs and the Prediction of Allergenicity. Immunol. Lett. 2007, 109, 47–55. [Google Scholar] [CrossRef] [PubMed]
  55. Ishikawa, M.; Ishida, M.; Shimakura, K.; Nagashima, Y.; Shiomi, K. Tropomyosin, the Major Oyster Crassostrea Gigas Allergen and Its IgE-Binding Epitopes. J. Food Sci. 1998, 63, 44–47. [Google Scholar] [CrossRef]
  56. Kumar, R.; Chaudhary, K.; Singh Chauhan, J.; Nagpal, G.; Kumar, R.; Sharma, M.; Raghava, G.P.S. An in Silico Platform for Predicting, Screening and Designing of Antihypertensive Peptides. Sci. Rep. 2015, 5, 12512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Charoenkwan, P.; Kanthawong, S.; Nantasenamat, C.; Hasan, M.D.M.; Shoombuatong, W. IDPPIV-SCM: A Sequence-Based Predictor for Identifying and Analyzing Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Peptides Using a Scoring Card Method. J. Proteome Res. 2020, 19, 4125–4136. [Google Scholar] [CrossRef] [PubMed]
  58. Trabuco, L.G.; Lise, S.; Petsalaki, E.; Russell, R.B. PepSite: Prediction of Peptide-Binding Sites from Protein Surfaces. Nucleic Acids Res. 2012, 40, W423–W427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Khatun, M.; Hasan, M.; Kurata, H. PreAIP: Computational Prediction of Anti-Inflammatory Peptides by Integrating Multiple Complementary Features. Front. Genet. 2019, 10, 129. [Google Scholar] [CrossRef] [Green Version]
  60. Manavalan, B.; Shin, T.H.; Kim, M.O.; Lee, G. AIPpred: Sequence-Based Prediction of Anti-Inflammatory Peptides Using Random Forest. Front. Pharmacol. 2018, 9, 276. [Google Scholar] [CrossRef] [Green Version]
  61. Gupta, S.; Sharma, A.K.; Shastri, V.; Madhu, M.K.; Sharma, V.K. Prediction of Anti-Inflammatory Proteins/Peptides: An Insilico Approach. J. Transl. Med. 2017, 15, 7. [Google Scholar] [CrossRef] [Green Version]
  62. Waghu, F.H.; Barai, R.S.; Gurung, P.; Idicula-Thomas, S. CAMPR3: A Database on Sequences, Structures and Signatures of Antimicrobial Peptides. Nucleic Acids Res. 2016, 44, D1094–D1097. [Google Scholar] [CrossRef]
  63. Schaduangrat, N.; Nantasenamat, C.; Prachayasittikul, V.; Shoombuatong, W. ACPred: A Computational Tool for the Prediction and Analysis of Anticancer Peptides. Molecules 2019, 24, 1973. [Google Scholar] [CrossRef] [Green Version]
  64. Huang, K.-Y.; Tseng, Y.-J.; Kao, H.-J.; Chen, C.-H.; Yang, H.-H.; Weng, S.-L. Identification of Subtypes of Anticancer Peptides Based on Sequential Features and Physicochemical Properties. Sci. Rep. 2021, 11, 13594. [Google Scholar] [CrossRef]
  65. Boopathi, V.; Subramaniyam, S.; Malik, A.; Lee, G.; Manavalan, B.; Yang, D.-C. MACPpred: A Support Vector Machine-Based Meta-Predictor for Identification of Anticancer Peptides. Int. J. Mol. Sci. 2019, 20, 1964. [Google Scholar] [CrossRef] [Green Version]
  66. Minkiewicz, P.; Iwaniak, A.; Darewicz, M. BIOPEP-UWM Database of Bioactive Peptides: Current Opportunities. Int. J. Mol. Sci. 2019, 20, 5978. [Google Scholar] [CrossRef] [Green Version]
  67. Shtatland, T.; Guettler, D.; Kossodo, M.; Pivovarov, M.; Weissleder, R. PepBank—A Database of Peptides Based on Sequence Text Mining and Public Peptide Data Sources. BMC Bioinform. 2007, 8, 280. [Google Scholar] [CrossRef] [Green Version]
  68. Liu, F.; Baggerman, G.; Schoofs, L.; Wets, G. The Construction of a Bioactive Peptide Database in Metazoa. J. Proteome Res. 2008, 7, 4119–4131. [Google Scholar] [CrossRef]
  69. Zamyatnin, A.A.; Borchikov, A.S.; Vladimirov, M.G.; Voronina, O.L. The EROP-Moscow Oligopeptide Database. Nucleic Acids Res. 2006, 34, D261–D266. [Google Scholar] [CrossRef] [Green Version]
  70. Li, Q.; Zhang, C.; Chen, H.; Xue, J.; Guo, X.; Liang, M.; Chen, M. BioPepDB: An Integrated Data Platform for Food-Derived Bioactive Peptides. Int. J. Food Sci. Nutr. 2018, 69, 963–968. [Google Scholar] [CrossRef]
  71. Roy, S.; Teron, R. BioDADPep: A Bioinformatics Database for Anti Diabetic Peptides. Bioinformation 2019, 15, 780–783. [Google Scholar] [CrossRef]
  72. Wang, G.; Li, X.; Wang, Z. APD3: The Antimicrobial Peptide Database as a Tool for Research and Education. Nucleic Acids Res. 2016, 44, D1087–D1093. [Google Scholar] [CrossRef]
  73. Lee, H.-T.; Lee, C.-C.; Yang, J.-R.; Lai, J.Z.C.; Chang, K.Y. A Large-Scale Structural Classification of Antimicrobial Peptides. BioMed. Res. Int. 2015, 2015, e475062. [Google Scholar] [CrossRef] [Green Version]
  74. Pirtskhalava, M.; Amstrong, A.A.; Grigolava, M.; Chubinidze, M.; Alimbarashvili, E.; Vishnepolsky, B.; Gabrielian, A.; Rosenthal, A.; Hurt, D.E.; Tartakovsky, M. DBAASP v3: Database of Antimicrobial/Cytotoxic Activity and Structure of Peptides as a Resource for Development of New Therapeutics. Nucleic Acids Res. 2021, 49, D288–D297. [Google Scholar] [CrossRef]
  75. Tyagi, A.; Tuknait, A.; Anand, P.; Gupta, S.; Sharma, M.; Mathur, D.; Joshi, A.; Singh, S.; Gautam, A.; Raghava, G.P.S. CancerPPD: A Database of Anticancer Peptides and Proteins. Nucleic Acids Res. 2015, 43, D837–D843. [Google Scholar] [CrossRef] [Green Version]
  76. Kapoor, P.; Singh, H.; Gautam, A.; Chaudhary, K.; Kumar, R.; Raghava, G.P.S. TumorHoPe: A Database of Tumor Homing Peptides. PLoS ONE 2012, 7, e35187. [Google Scholar] [CrossRef]
Molecules 28 00651 g001 550
Figure 1. Virtual peptide products from 13 digested oyster proteins using (a) ExPASy PeptideCutter and (b) BIOPEP-UVM’s “Enzyme Action” tool.
Figure 1. Virtual peptide products from 13 digested oyster proteins using (a) ExPASy PeptideCutter and (b) BIOPEP-UVM’s “Enzyme Action” tool.
Molecules 28 00651 g001
Table
Table 1. Digestive enzyme selection in BIOPEP and ExPASy PeptideCutter.
Table 1. Digestive enzyme selection in BIOPEP and ExPASy PeptideCutter.
Digestion PlatformEnzyme NameEC NumberCleavage ResiduesAdditional Information and References
BIOPEP Enzyme Action ToolPepsin (pH > 2)3.4.23.1 C-terminus of F, L, G, Y, A, E, Q, T, N, K, D, M;
N-terminus of V, I		MEROPS A01.001 show broad cleavage specificity
Trypsin3.4.21.4 C-terminus of K, R P after K blocks enzyme action [20]
Chymotrypsin (A)3.4.21.1 C-terminus of F, Y, W, L, N, H, MP after Y, P or M after W, P after F, P after L block enzyme action [21].
ExPASy
PeptideCutter		Pepsin (pH > 2)3.4.23.1 Broad specificity with preference at F, Y, W, L in position P1 or P1’ [20]Lost specificity at pH >= 2
Trypsin3.4.21.4 Preferentially cleaves R and K at P1P at P1′ blocks enzyme action but not when K and W or R and M are at P1 and P2 at the same time. If K at P1, enzyme action is blocked when D and D, C and D, C and H, or C and Y are at P2 and P1′ respectively. When R is at P1, enzyme action is blocked with R and H, C and K, or R and R are at P2 and P1′respectively.
Chymotrypsin (low specificity)3.4.21.1Preferential at F, Y, W, L, M at P1Exceptions: P at P1′; M or P at P1′ when is W is at P1; Y at P1′ when M is at P1; when H is at P1, D, M or W also blocks the cleavage.
Table
Table 2. Peptide candidate long list pre-screened for size range, toxicity, bitterness, stability, and novelty.
Table 2. Peptide candidate long list pre-screened for size range, toxicity, bitterness, stability, and novelty.
IdentifierToxicityBitternessStabilityNovelty Finds
Peptide No.Source Protein Accession NumberPeptide Sequence# ResiduesToxinPrediBitter-SCMPLifePredHLPBIOPEP DatabasePepBankEROP-MOSCOWBioPepDB
FASTAScoreDescriptorScoreDescriptorHalf-Life in Blood (s)Intestinal Half-Life (s)Stability
>O1O17320NSPAM5−0.58Non-Toxin308non-Bitter832.111.553High0000
>O2P0DUE1PQSCR5−0.58Non-Toxin251.25non-Bitter826.311.425High0000
>O3A9XE49ICPSS5−0.67Non-Toxin320.25non-Bitter833.811.358High0000
>O4XP_034310988.1CTGAI5−0.63Non-Toxin285.25non-Bitter839.411.32High0000
>O5A9XE49CEPVY5−0.86Non-Toxin229non-Bitter847.511.26High0000
>O6XP_034310988.1QACID5−0.55Non-Toxin320.25non-Bitter840.711.477High0000
>O7P0DUE1SVPVL5−0.97Non-Toxin283.25non-Bitter836.511.192High0000
>O8XP_034310988.1QCNGV5−0.61Non-Toxin322.75non-Bitter826.411.513High0000
>O9XP_034310988.1STHPH5−0.73Non-Toxin308non-Bitter834.811.292High0000
>O10XP_034310988.1IEKPM5−0.82Non-Toxin330.25non-Bitter838.312.38High0000
>O11XP_034310988.1AGSVP5−0.67Non-Toxin321.5non-Bitter913.011.316High0000
>O12Q4GWV4CDAAT5−0.73Non-Toxin278non-Bitter835.011.239High0000
>O13Q4GWV4VSADM5−0.8Non-Toxin327.5non-Bitter838.011.27High0000
>O14O17320SSSSL5−0.8Non-Toxin312.75non-Bitter834.811.374High0000
>O15P0DUE1SEPNI5−0.82Non-Toxin229non-Bitter832.511.595High0000
>O16O17320TVPIY5−1.1Non-Toxin330.5non-Bitter823.911.402High0000
>O17P0DUE1SPSST5−0.88Non-Toxin325.25non-Bitter835.011.249High0000
>O18XP_034310988.1DAANR5−0.89Non-Toxin275.5non-Bitter835.611.251High0000
>O19Q20A06CDAVT5−0.81Non-Toxin322.75non-Bitter831.711.054High0000
>O20XP_034310988.1INQGA5−0.9Non-Toxin320non-Bitter845.011.68High0000
>O21XP_034310988.1QSDVR5−0.72Non-Toxin318.5non-Bitter838.711.471High0000
>O22XP_011417566.1IDQNR5−0.74Non-Toxin332.5non-Bitter858.611.386High0000
>O23XP_011417566.1DKDGK5−0.71Non-Toxin325.25non-Bitter835.311.295High0000
>O24XP_034310988.1SEIDR5−0.96Non-Toxin317.5non-Bitter824.711.375High0000
>O25XP_034310988.1DNQIK5−0.82Non-Toxin302.75non-Bitter915.212.152High0000
>O26XP_034310988.1AADER5−0.96Non-Toxin270.5non-Bitter865.311.306High0000
>O27XP_034310988.1QQQIK5−0.89Non-Toxin308.25non-Bitter834.811.405High0000
>O28XP_034310988.1ENQSM5−0.79Non-Toxin300.75non-Bitter840.311.834High0000
>O29XP_034310988.1ANDNT5−0.78Non-Toxin276non-Bitter834.311.807High0000
>O30XP_034310988.1GAVDK5−0.69Non-Toxin312.75non-Bitter832.311.239High0000
>O31Q95WY0DEAAR5−0.99Non-Toxin278non-Bitter865.311.256High0000
>O32XP_011429256.1DAAER5−0.95Non-Toxin268non-Bitter865.311.587High0000
>O33XP_034310988.1DSEQR5−1Non-Toxin327.75non-Bitter846.212.5High0000
>O34XP_034310988.1EGQIK5−0.77Non-Toxin269.25non-Bitter829.311.409High0000
>O35Q95WY0DAENR5−0.7Non-Toxin332.75non-Bitter824.811.525High0000
>O36XP_034310988.1VAANI5−0.96Non-Toxin256non-Bitter834.911.252High0000
>O37XP_011417566.1AQQQK5−0.87Non-Toxin308.5non-Bitter834.811.405High0000
>O38XP_011429256.1DDESR5−0.64Non-Toxin221.75non-Bitter834.311.567High0000
>O39XP_034310988.1EQTQP5−1.18Non-Toxin273.25non-Bitter835.111.335High0000
>O40XP_011429256.1SVSER5−1.02Non-Toxin300non-Bitter835.011.138High0000
>O41XP_011429256.1ETDIR5−0.85Non-Toxin320non-Bitter836.411.07High0000
>O42XP_011429256.1AAEER5−0.85Non-Toxin278non-Bitter839.412.234High0000
>O43XP_011429256.1EANQA5−0.96Non-Toxin307.75non-Bitter852.711.884High0000
>O44XP_011429256.1TEINR5−0.86Non-Toxin332.5non-Bitter830.211.509High0000
>O45XP_034310988.1EQAER5−1.08Non-Toxin318non-Bitter818.612.042High0000
>O46P0DUE1EESGK5−0.8Non-Toxin254.25non-Bitter832.511.8High0000
>O47XP_011429256.1DAETK5−0.83Non-Toxin330non-Bitter834.811.67High0000
>O48XP_034310988.1AEVTR5−0.71Non-Toxin330.25non-Bitter847.311.154High0000
>O49XP_011429256.1VQVDD5−0.81Non-Toxin261.75non-Bitter834.811.804High0000
>O50Q95WY0EETIR5−0.66Non-Toxin327.5non-Bitter832.911.541High0000
>O51XP_034310988.1ITDEA5−0.94Non-Toxin332.5non-Bitter829.811.499High0000
>O52XP_034310988.1AAESE5−0.89Non-Toxin197non-Bitter833.611.548High0000
>O53XP_034310988.1EAEAK5−0.79Non-Toxin322.5non-Bitter835.711.455High0000
>O54XP_034310988.1AETQK5−0.77Non-Toxin313non-Bitter856.111.544High0000
>O55Q95WY0EEASK5−0.73Non-Toxin328.75non-Bitter831.111.462High0000
>O56XP_034310988.1TESTK5−1.01Non-Toxin269non-Bitter817.312.175High0000
>O57A9XE49CSGCVP6−0.72Non-Toxin305.8non-Bitter834.711.502High0000
>O58Q20A05GCPGDQ6−0.64Non-Toxin327.2non-Bitter844.713.646High0000
>O59XP_034310988.1SVTPSF6−0.95Non-Toxin312.4non-Bitter830.411.106High0000
>O60O17320CDVDIR6−1.1Non-Toxin323non-Bitter828.711.446High0000
>O61XP_034310988.1CIIPNE6−0.41Non-Toxin272.8non-Bitter834.211.451High0000
>O62XP_034310988.1CVAINP6−0.63Non-Toxin272non-Bitter828.711.164High0000
>O63XP_034310988.1DDIQQM6−1.08Non-Toxin259.6non-Bitter835.611.138High0000
>O64A9XE49AAAVHM6−0.94Non-Toxin232non-Bitter834.911.269High0000
>O65XP_034310988.1QQPAER6−1.37Non-Toxin276non-Bitter835.611.478High0000
>O66XP_011429256.1ASADAK6−0.72Non-Toxin312non-Bitter834.911.164High0000
>O67O17320ESSGIH6−0.87Non-Toxin274.6non-Bitter833.511.314High0000
>O68P0DUE1ICNEIK6−0.7Non-Toxin329.2non-Bitter836.111.33High0000
>O69XP_034310988.1QADEDR6−0.99Non-Toxin323.2non-Bitter839.911.874High0000
>O70XP_034310988.1VSSSSM6−0.76Non-Toxin315non-Bitter834.911.376High0000
>O71XP_011429256.1AAAQAA6−0.92Non-Toxin190.6non-Bitter834.811.337High0000
>O72XP_011429256.1EEASGM6−0.94Non-Toxin320non-Bitter830.111.463High0000
>O73XP_034310988.1ADQIDQ6−0.69Non-Toxin321non-Bitter835.911.355High0000
>O74Q95WY0QECQTK6−0.54Non-Toxin304.6non-Bitter838.011.592High0000
>O75XP_011429256.1ETAANM6−0.91Non-Toxin293.2non-Bitter835.711.302High0000
>O76XP_034310988.1SQQIEK6−1.04Non-Toxin292.6non-Bitter848.012.262High0000
>O77XP_011429256.1AAEVNR6−0.88Non-Toxin289.6non-Bitter852.511.335High0000
>O78P0DUE1AVDDSH6−0.77Non-Toxin285.4non-Bitter832.712.198High0000
>O79XP_011429256.1GETSQR6−1.06Non-Toxin300.4non-Bitter828.911.534High0000
>O80P0DUE1DSVESR6−0.78Non-Toxin317.2non-Bitter834.112.269High0000
>O81XP_011417566.1AATSNV6−0.98Non-Toxin255.2non-Bitter825.211.4High0000
>O82O17320VAIQAV6−1.12Non-Toxin280.6non-Bitter835.011.432High0000
>O83XP_034310988.1SAQVSS6−0.59Non-Toxin294.4non-Bitter842.511.323High0000
>O84XP_034310988.1SQESTD6−0.95Non-Toxin257.6non-Bitter828.211.728High0000
>O85XP_034310988.1IDECEE6−0.06Non-Toxin298non-Bitter834.811.455High0000
>O86XP_011429256.1QAANES6−1.03Non-Toxin226.8non-Bitter836.411.3High0000
>O87Q95WY0EAAEAK6−0.88Non-Toxin283.4non-Bitter837.011.426High0000
>O88XP_011429256.1QVQVDD6−0.85Non-Toxin255.6non-Bitter834.811.518High0000
>O89Q95WY0ATEAER6−1.16Non-Toxin319non-Bitter853.111.869High0000
>O90XP_034310988.1EDAEER6−0.99Non-Toxin333non-Bitter832.011.855High0000
>O91XP_034310988.1QAEEDK6−0.81Non-Toxin331.2non-Bitter847.912.09High0000
>O92Q95WY0AITEVD6−1.17Non-Toxin301.4non-Bitter831.911.789High0000
>O93XP_034310988.1EAQVSS6−0.89Non-Toxin300.4non-Bitter837.511.275High0000
>O94XP_034310988.1ESENDE6−0.78Non-Toxin272.4non-Bitter835.111.929High0000
>O95Q95WY0QTATEK6−1.13Non-Toxin306.4non-Bitter831.311.662High0000
>O96XP_011429256.1VINTEK6−0.82Non-Toxin297.8non-Bitter850.911.557High0000
>O97XP_034310988.1EEAEAA6−0.9Non-Toxin299.4non-Bitter834.911.561High0000
>O98XP_034310988.1QTEQDS6−1.33Non-Toxin320.8non-Bitter834.112.184High0000
>O99O17320TTTAER6−0.92Non-Toxin320.8non-Bitter834.711.464High0000
>O100P0DUE1SPSSTNM7−0.83Non-Toxin328.5non-Bitter836.011.249High0000
>O101A9XE49ICPSSIK7−0.8Non-Toxin313.67non-Bitter830.411.358High0000
>O102XP_034310988.1DAEIANM7−0.56Non-Toxin320non-Bitter830.611.398High0000
>O103XP_011429256.1EGDIAAM7−0.92Non-Toxin282non-Bitter846.911.856High0000
>O104XP_011417566.1GSTPDDK7−0.57Non-Toxin304.5non-Bitter884.111.373High0000
>O105XP_034310988.1ESDIQAM7−1.01Non-Toxin278.5non-Bitter875.811.265High0000
>O106XP_011429256.1DSDIQTK7−1.39Non-Toxin315.33non-Bitter875.112.027High0000
>O107Q7M456IPDSVVG7−1.04Non-Toxin314.33non-Bitter828.412.082High0000
>O108XP_034310988.1AVADAAR7−0.94Non-Toxin284non-Bitter835.011.225High0000
>O109O17320GDEDIAA7−0.88Non-Toxin283.67non-Bitter836.912.021High0000
>O110XP_034310988.1SSVSVTR7−0.77Non-Toxin323.33non-Bitter835.211.211High0000
>O111P0DUE1SDTPVTS7−1Non-Toxin290.33non-Bitter807.211.628High0000
>O112XP_034310988.1ANTEVQM7−0.92Non-Toxin252non-Bitter829.711.641High0000
>O113XP_034310988.1GDEITVK7−0.86Non-Toxin318.33non-Bitter833.812.4High0000
>O114XP_011417566.1GSSSEEA7−0.49Non-Toxin318.33non-Bitter831.411.297High0000
>O115XP_034310988.1TESIIAK7−0.73Non-Toxin296.33non-Bitter846.312.392High0000
>O116XP_011429256.1ESTEASM7−0.88Non-Toxin283.5non-Bitter830.912.031High0000
>O117XP_034310988.1EEAEAQA7−0.84Non-Toxin323.67non-Bitter837.511.561High0000
>O118XP_034310988.1EEEQESK7−0.68Non-Toxin312.83non-Bitter834.911.716High0000
>O119XP_034310988.1GPSSNPNF8−0.73Non-Toxin286.57non-Bitter832.411.282High0000
>O120P0DUE1VDDLPPPL8−0.72Non-Toxin261.14non-Bitter835.512.204High0000
>O121XP_034310988.1APNAIPQG8−0.61Non-Toxin280.71non-Bitter833.711.519High0000
>O122A9XE49QEGCTCVR8−0.63Non-Toxin324.71non-Bitter806.111.643High0000
>O123Q7M456YPPVHDNN8−0.59Non-Toxin296.57non-Bitter832.411.606High0000
>O124XP_034310988.1QPGVIDAA8−1.31Non-Toxin318.14non-Bitter864.712.056High0000
>O125O17320DSGDGVSH8−1.05Non-Toxin312.29non-Bitter823.313.856High0000
>O126O17320VVDNGSGM8−0.57Non-Toxin326.71non-Bitter808.811.377High0000
>O127Q7M456PSSDTESK8−0.89Non-Toxin290.29non-Bitter846.411.411High0000
>O128Q6L6Q6QQGCNVNS8−0.45Non-Toxin306non-Bitter830.511.425High0000
>O129XP_034310988.1IAGADIET8−0.65Non-Toxin320.86non-Bitter842.611.209High0000
>O130NP_001295835SVVANNIK8−0.97Non-Toxin318.57non-Bitter818.211.147High0000
>O131XP_011429256.1DEEIDSIR8−0.82Non-Toxin325non-Bitter833.011.544High0000
>O132XP_034310988.1TSVSSSSM8−0.68Non-Toxin317.86non-Bitter835.511.094High0000
>O133XP_034310988.1QTDTANEM8−0.54Non-Toxin324.57non-Bitter828.511.376High0000
>O134P0DUE1DSIADESS8−0.71Non-Toxin283non-Bitter832.913.6High0000
>O135O17320VGDEAQSK8−0.63Non-Toxin299.71non-Bitter902.112.04High0000
>O136XP_034310988.1DEEDAAAD8−1.04Non-Toxin282.71non-Bitter835.011.586High0000
>O137O17320TTAASSSS8−0.65Non-Toxin285.86non-Bitter834.911.159High0000
>O138Q4GWV4CTCTDCNGK9−0.5Non-Toxin321non-Bitter819.111.392High0000
>O139O17320VAPEEHPVL9−0.59Non-Toxin311.75non-Bitter828.012.088High0000
>O140XP_034310988.1ASQDEVIAR9−1.14Non-Toxin309.12non-Bitter937.711.243High0000
>O141Q7M456EVSETTCPR9−1.11Non-Toxin312.25non-Bitter800.311.3High0000
>O142XP_011429256.1GTSPSTQNR9−1.05Non-Toxin330.25non-Bitter816.212.136High0000
>O143XP_034310988.1ITGESGAGK9−1.28Non-Toxin278.5non-Bitter1058.511.721High0000
>O144XP_034310988.1VGAEIQSSK9−0.92Non-Toxin308.25non-Bitter873.211.519High0000
>O145XP_034310988.1EESQDSIEQ9−1.5Non-Toxin295.5non-Bitter838.811.576High0000
>O146XP_011429256.1EEESESASN9−0.6Non-Toxin240.75non-Bitter834.811.517High0000
>O147XP_034310988.1QTQIEEEQR9−1.08Non-Toxin326.25non-Bitter835.512.215High0000
>O148P0DUE1ESSDDTTVCM10−0.2Non-Toxin303.67non-Bitter801.211.398High0000
>O149NP_001295835QVQNDQASQR10−0.98Non-Toxin290.44non-Bitter838.512.22High0000
>O150XP_011429256.1QIDEAEDVAN10−0.69Non-Toxin321.78non-Bitter877.011.482High0000
>O151XP_011429256.1EIVTQAEDDR10−1.19Non-Toxin330.33non-Bitter852.411.067High0000
Table
Table 3. Top C. gigas bioactive peptide candidate shortlist with bioactivity prediction results.
Table 3. Top C. gigas bioactive peptide candidate shortlist with bioactivity prediction results.
BioactivityIdentifierActivity Prediction
Oyster Protein SourcePeptide Sequence# ResiduesPredictorScore
Accession NumberName
AntihypertensiveA9XE49Interleukin 17-like protein (CgIL-17)CEPVY5AHTpin1.44
XP_034310988.1Myosin Heavy Chain, Striated MuscleQQQIK51.44
O17320ActinVAPEEHPVL91.37
XP_011417566.1Myosin Regulatory Light Chain B, Smooth Adductor Muscle Isoform X1 AQQQK51.27
XP_034310988.1Myosin Heavy Chain, Striated MuscleSTHPH51.02
DPPIV-InhibitoryXP_034310988.1Myosin Heavy Chain, Striated MuscleEQTQP5iDPPIV-SCM418.75
Q7M456Ribonuclease Oy (RNase Oy) (EC 3.1.27.-)YPPVHDNN8373
O17320ActinVAPEEHPVL9360
O17320ActinNSPAM5359.25
P0DUE1Stimulator of interferon genes protein (TIR-STING) (Probable NAD(+) hydrolase) (EC 3.2.2.6)SVPVL5350
Anti-inflammatoryQ4GWV4Defensin Cg-Defm (Cg-Def) (Mantle defensin)CTCTDCNGK9PreAIP0.613
XP_034310988.1Myosin Heavy Chain, Striated MuscleQACID5PreAIP0.534
A9XE49Interleukin 17-like protein (CgIL-17)QEGCTCVR8PreAIP0.521
P0DUE1Stimulator of interferon genes protein (TIR-STING) (Probable NAD(+) hydrolase) (EC 3.2.2.6)ICNEIK6PreAIP0.491
Antiinflam3.356
AntimicrobialXP_011429256.1Paramyosin Isoform X2EEESESASN9CAMP-SVM1
CAMP-RF0.6545
ADAM-SVM-
XP_011429256.1Paramyosin Isoform X2EEASGM6CAMP-SVM1
CAMP-RF0.6395
ADAM-SVM-
XP_011429256.1Paramyosin Isoform X2ETAANM6CAMP-SVM1
CAMP-RF0.554
ADAM-SVM-
ADAM-SVM-
XP_011417566.1Myosin Regulatory Light Chain B, Smooth Adductor Muscle Isoform X1 DKDGK5CAMP-SVM1
CAMP-RF0.5475
ADAM-SVM-
Q95WY0Tropomyosin (Allergen Cra g 1.03) (allergen Cra g 1) (Fragment)SVVANNIK8DBAASPv3.0-
ADAM-SVM-
Anti-cancerA9XE49Interleukin 17-like protein (CgIL-17)CSGCVP6ACPred0.947
iDACP0.5196
mACPpred0.9812
Q20A06Hemocyte defensin Cg-Defh1 (Fragment)CQSIGCR7ACPred0.935
iDACP0.5196
mACPpred0.8374
Q4GWV4Defensin Cg-Defm (Cg-Def) (Mantle defensin)CTCTDCNGK9ACPred0.985
iDACP0.5574
mACPpred0.9253
Table
Table 4. PepSite2 analysis using ACE1 (PDB: 1O86) as the target protein.
Table 4. PepSite2 analysis using ACE1 (PDB: 1O86) as the target protein.
Peptide SequenceAHTpin SVM ScoreRanking/Selection CriteriaPepSite2 p-ValuePotential Binding Sites of ACE ProteinPotential Binding Residues on Peptide
CEPVY1.44AHTpin SVM Score > 1, Rank #16.94 × 10−4H353, H383 *, H387 *, F409, H410, E411 *, A412, I413, G414, D415, F457, K511, H513, Y523, S526, F527, Q281, A354, E384, Y520, S355, Y146, F512, A356, Y146C1, E2, P3, V4, Y5
QQQIK1.44AHTpin SVM Score > 1, Rank #21.37 × 10−4Q281, H353, A354, H383 *Q1, Q2, Q3, I4, K5
EVSETTCPR1.43AHTpin SVM Score > 1, Rank #36.96 × 10−4Q281, H353, A354, S355, A356, H383 *, E384, H387 *, F391, E411 *, F457, K511, H513, Y520, H410, R522, W59, Y360E1, V2, S3, E4, T5, T6, C7, P8, R9
VAPEEHPVL1.37AHTpin SVM Score > 1, Rank #42.30 × 10−4Y146, W279, Q281, H353, H383 *, H387 *, H410, E411 *, A412, D415, F457, F460, K511, F512, H513, Y520, Y523, S526, F527, E384, A354, S355, A356, R522V1, A2, P3, E4, E5, H6, P7, V8, L9
PQSCR1.33AHTpin SVM Score > 1, Rank #55.62 × 10−5W279, Q281, H353, H383 *, E411 *, D415, F457, F460, K511, H513, Y520, Y523, S526, F527, A354, E384, H387 *, F409, H410, A412, I413, G414, Q530P1, Q2, S3, C4, R5
AQQQK1.27AHTpin SVM Score > 1, Rank #67.32 × 10−5Q281, H353, A354, H383 *, E384, H387 *, E411 *, F457, K511, H513, Y520, Y523, F527, W279, F460, F512 A1, Q2, Q3, Q4, K5
GPSSNPNF1.17AHTpin SVM Score > 1, Rank #71.07 × 10−4W279, Q281, H353, A354, S355, H383 *, E384, H387 *, E411 *, F457, F460, K511, H513, Y520, Y523, N66, A356, W357, F391, F512, D358, Y360, F527 G1, P2, S3, S4, N5, P6, N7, F8
EQTQP1.14AHTpin SVM Score > 1, Rank #82.71 × 10−5Q281, H353, A354, H383 *, E384, H387 *, E411 *, F457, F460, K511, H513, Y520, F527, F512, Y523, D415, S526, S355E1, Q2, T3, Q4, P5
STHPH1.02AHTpin SVM Score > 1, Rank #95.55 × 10−5Q281, H353, A354, S355, H383 *, E384, H387 *, E411 *, F457, H513, Y520, Y523, K511, W279, F460S1, T2, H3, P4, H5
Notes: * denotes residue of active sites. The active site of ACE revolves around this zinc ion. Zinc ligands of ACE consist of H383, H387, E411 and a water molecule [22]. In addition, the water molecule was also bound to E384 via hydrogen bonds. These main stabilizing residues are Q281, H353, A354, K511, H513, Y520, and Y523 [22,23].
Table
Table 5. PepSite2 analysis using DPP-IV (PDB: 2ONC) as the target protein.
Table 5. PepSite2 analysis using DPP-IV (PDB: 2ONC) as the target protein.
Peptide SequenceiDPPIV-SCM ScoreRanking/Selection CriteriaPepSite2 p-ValuePotential Binding Sites of DPP-IV (Enzyme Protein)Potential Binding Residues (Peptide)
EQTQP418.75iDPPIV-SCM Score >= 350, Rank #15.18 × 10−3Y48, W627, W629, V653, I703, I742, H748, I751, Y752, M755, Y547, S630 *, H740 *, G741 E1, Q2, T3, Q4, P5
TVPIY389.25iDPPIV-SCM Score >= 350, Rank #21.78 × 10−2Y48, W627, W629, V653, I703, I742, H748, I751, Y752, M755, G741, F357, Y547, Y666 T1, V2, P3, I4, Y5
VDDLPPPL385iDPPIV-SCM Score >= 350, Rank #36.52 × 10−2F357, Y547, P550, W629, Y631, Y666, Y670, G741, Y752, Y48, W627, H748V1, D2, D3, L4, P5, P6, P7, L8
YPPVHDNN373iDPPIV-SCM Score >= 350, Rank #43.23 × 10−2F357, Y547, P550, C551, Y585, W629, S630 *, Y631, Y662, Y666, Y670, H740 *, Y48, W627, H748, Y752, G741Y1, P2, P3, V4, H5, D6, N7, N8
VAPEEHPVL360iDPPIV-SCM Score >= 350, Rank #58.93 × 10−2F357, Y547, P550, W627, W629, S630 *, Y631, Y662, Y666, Y670, H740 *, Y752, Y48, M733, W734, Y735, H750, G741, H748 V1, A2, P3, E4, E5, H6, P7, V8, L9
NSPAM359.25iDPPIV-SCM Score >= 350, Rank #61.22 × 10−2Y48, W627, W629, H740 *, Y752, H748, S630 *, Y631, V656, W659, Y662, Y666, Y547N1, S2, P3, A4, M5
SVPVL350iDPPIV-SCM Score >= 350, Rank #78.85 × 10−3Y48, W627, W629, H740 *, Y752, S630 *, G741, H748S1, V2, P3, V4, L5
Notes: * denotes residue of active sites. The catalytic domain is from Q508 to P766 whereas the main catalytic residues are S630, D708, and H740 [24].
Table
Table 6. Full list C. gigas proteins selection for analysis.
Table 6. Full list C. gigas proteins selection for analysis.
Database SourceAccession # aProtein NameLength (Residues)Mass (Da)
Swiss-ProtQ4GWV4Defensin Cg-Defm (Cg-Def) (Mantle defensin)657008
P0DUE1Stimulator of interferon genes protein (TIR-STING) (Probable NAD(+) hydrolase) (EC 3.2.2.6)41547,031
Q6L6Q6Lysozyme (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase) (Invertebrate-type lysozyme)13715,274
Q20A05Hemocyte defensin Cg-Defh2 (Fragment)606439
Q20A06Hemocyte defensin Cg-Defh1 (Fragment)606587
Q7M456Ribonuclease Oy (RNase Oy) (EC 3.1.27.-)21324,360
Q95WY0Tropomyosin (Allergen Cra g 1.03) (allergen Cra g 1) (Fragment)23326,867
A9XE49Interleukin 17-like protein (CgIL-17)20021,551
O17320Actin37641,792
NCBI RefSeqXP_034310988.1Myosin Heavy Chain, Striated Muscle1986222,660
XP_011429256.1Paramyosin Isoform X2886102,210
NP_001295835Tropomyosin Isoform X128433,020
XP_011417566.1Myosin Regulatory Light Chain B, Smooth Adductor Muscle Isoform X116620,580
a Accession numbers were retrieved from UniProt Knowledgebase and NCBI Refseq databases respectively.
Table
Table 7. Bioactivity prediction servers and databases used for bioactivity screening in the current study.
Table 7. Bioactivity prediction servers and databases used for bioactivity screening in the current study.
Platform NamePurposeURLCitation
AHTpinAnti-hypertensive peptide prediction http://crdd.osdd.net/raghava/ahtpin/, accessed on 15 January 2022[56]
iDPPIV-SCMDPP-IV inhibitory peptide prediction http://camt.pythonanywhere.com/iDPPIV-SCM/, accessed on 15 January 2022[57]
PepSite2Peptide-protein binding interaction modelinghttp://pepsite2.russelllab.org/, accessed on 5 May 2022[58]
PreAIPAnti-inflammatory peptide prediction http://kurata14.bio.kyutech.ac.jp/PreAIP/, accessed on 18 January 2022[59]
AIPpredAnti-inflammatory peptide prediction http://www.thegleelab.org/AIPpred/, accessed on 1 March 2022[60]
AntiinflamAnti-inflammatory peptide prediction http://metagenomics.iiserb.ac.in/antiinflam/, accessed on 1 March 2022[61]
CAMP-R3Antimicrobial peptide predictionhttp://www.camp.bicnirrh.res.in/predict/, accessed on 20 January 2022[62]
ACPredAnti-cancer peptide predictionhttp://codes.bio/acpred/, accessed on 11 March 2022[63]
iDACPAnti-cancer peptide predictionhttp://mer.hc.mmh.org.tw/iDACP/, accessed on 11 March 2022[64]
mACPpred Anti-cancer peptide predictionhttp://www.thegleelab.org/mACPpred/ACP.html, accessed on 13 March 2022[65]
BIOPEP-UVMComprehensive BAP databasehttps://biochemia.uwm.edu.pl/en/biopep-uwm-2, accessed on 1 February 2022 [66]
PepBankComprehensive BAP databasehttp://pepbank.mgh.harvard.edu, accessed on 10 March 2022[67]
PeptideDBComprehensive BAP databasehttp://www.peptides.be, accessed on 10 March 2022[68]
EROP-Moscow Comprehensive BAP databasehttp://erop.inbi.ras.ru/index.html, accessed on 10 March 2022[69]
BioPepDBComprehensive BAP databasehttp://bis.zju.edu.cn/biopepdbr/index.php, accessed on 11 April 2022[70]
AHTpDB Anti-hypertensive peptide databasehttp://crdd.osdd.net/raghava/ahtpdb. accessed on 15 January 2022[56]
BioDADPepAnti-diabetic peptide databasehttps://omicsbase.com/BioDADPep. accessed on 11 April 2022[71]
APD3Antimicrobial peptide databasehttps://aps.unmc.edu, accessed on 20 January 2022[72]
ADAMAntimicrobial peptide databasehttp://bioinformatics.cs.ntou.edu.tw/adam, accessed on 12 May 2022[73]
DBAASP v3.0 Antimicrobial peptide databasehttps://dbaasp.org, accessed on 12 May 2022[74]
CancerPPDAnti-cancer peptide databasehttp://crdd.osdd.net/raghava/cancerppd, accessed on 27 March 2022[75]
TumorHoPeAnti-cancer peptide databasehttps://webs.iiitd.edu.in/raghava/tumorhope/pepsearch.php, accessed on 27 March 2022[76]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhou, L.; Mendez, R.L.; Kwon, J.Y. In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas). Molecules 2023, 28, 651. https://doi.org/10.3390/molecules28020651

AMA Style

Zhou L, Mendez RL, Kwon JY. In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas). Molecules. 2023; 28(2):651. https://doi.org/10.3390/molecules28020651

Chicago/Turabian Style

Zhou, Leyi, Rufa L. Mendez, and Jung Yeon Kwon. 2023. "In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas)" Molecules 28, no. 2: 651. https://doi.org/10.3390/molecules28020651

APA Style

Zhou, L., Mendez, R. L., & Kwon, J. Y. (2023). In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas). Molecules, 28(2), 651. https://doi.org/10.3390/molecules28020651

Article Metrics

Back to TopTop